Develops durable, long-acting self-amplifying RNA (saRNA) therapeutics delivered via a proprietary hepatocyte-targeted lipid nanoparticle platform for chronic genetic liver diseases and other indications. Lead program targets Crigler‑Najjar Syndrome Type 1 to demonstrate in vivo proof-of-concept for sustained high-level protein expression with improved safety suitable for lifelong, repeat dosing.